Aurinia Pharmaceuticals welcomes Dr. Brinda Balakrishnan to its Board of Directors

– CANADA, Victoria –  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH | TSX: AUP) today announced the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to its Board of Directors effective June 14, 2021.

Dr. Balakrishnan is Group VP, Corporate and Business Development of BioMarin Pharmaceutical Inc., a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare disorders. At BioMarin, Dr. Balakrishnan leads initiatives on corporate strategy, mergers, and acquisitions, partnering, and licensing.

“On behalf of the entire Company, it is an honor to welcome Dr. Balakrishnan to Aurinia’s Board of Directors,” said CEO, Peter Greenleaf. “With her rich experience in medicine, biotech business development and the rare disease space, we are eager to leverage her input and insights as we continue in our mission to support and better treat people suffering with rare, autoimmune diseases, including lupus nephritis.”

Dr. Brinda Balakrishnan

Dr. Balakrishnan has been at BioMarin since 2016. Before joining BioMarin, Dr. Balakrishnan was the co-founder and Vice President of corporate strategy and product development at Vision Medicines, Inc., a start-up focused on developing treatments for rare ophthalmic diseases. Before Vision Medicines, she spent two years as a consultant at McKinsey & Company in the healthcare practice, serving clients across small biotech, large pharma, and healthcare provider groups on topics related to corporate strategy, corporate and business development, and operations. Before McKinsey, Dr. Balakrishnan was in business development at Genzyme.

“I am delighted to join the Board of Directors of Aurinia,” said Dr. Balakrishnan. “The Company is at an exciting moment in its evolution, and I look forward to working with the Board and management team as Aurinia continues on its mission to serve people suffering from debilitating autoimmune diseases.”

Dr. Balakrishnan earned a B.S. degree from the Massachusetts Institute of Technology in chemical engineering and a Ph.D. from MIT in biomedical engineering and chemical engineering. She also earned her M.D. degree from Harvard Medical School and conducted her medical training in internal medicine at Beth Israel Deaconess Medical Center in Boston, a Harvard hospital.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.